 Participants must be people of either gender aged 18 years or older diagnosed with a life-threatening cancer or non-dementing neurological illness and anxiety resulting from confronting this illness. Eighteen participants will be enrolled in the study. Five of 18 participants will receive placebo and 13 will receive MDMA. 